Influential Medicine Providing Access to Clinical Trials (IMPACT)

Get more information about other programs, and about applying for a Blood Cancer United research funding.

Grant requirements

Reporting schedule: Progress, Conflicts Disclosure, and Financial Reports are required for each year of the grant, and Publications Reports are required each quarter. The reporting schedule for your particular grant is printed on your Grant Agreement and available under Reports Due in the Blood Cancer United Research Portal (FLUXX). Below is an example of a typical schedule for an IMPACT grant starting July 1, 2020.

Report submission: Blood Cancer United research grant reporting is conducted through the Blood Cancer United Research Portal (FLUXX). Access this portal using the same username and password that were used during the application process.
Individuals responsible for submitting reports must be manually added to each individual grant record in our system in order for them to have reporting access for each grant. Contact [email protected] to update reporting access for your grant.

Progress Reports and Publications Reports should be submitted by the researcher (the PI). Financial Reports should be submitted by the financial officer, and Conflicts Disclosure Reports should be submitted by the Grantee.

Researchers and administrators should be careful to follow all instructions on the report web form and downloadable template. Reports that fail to follow instructions will be returned for revision, which may delay grant payment. Do not save templates for future use; the templates are subject to change and therefore must be newly downloaded for each submission.

Report Submission Guide (PDF)

Download the Report Submission Guide for detailed instructions on submitting a report in the Blood Cancer United Research Portal (FLUXX).
Note: FLUXX recently updated the grantee portal view, so the pages will visually be different from the screenshots shown in this guide. This change is aesthetic only; the process for submitting reports remains unchanged.

Milestones and annual assessment

Blood Cancer United Research staff will assess the IMPACT Program team and the progress made against the Milestones. Blood Cancer United Research staff will make a recommendation as to the level of continued funding. In the case where sufficient progress is being made, the funding will remain the same. In the unlikely event that progress is not sufficient, a written warning will be provided, which may result in future funding being reduced if progress does not improve. After the second semi-annual assessment of the year, Blood Cancer United Research staff will work with the Grantee to establish Milestones for the coming year. These Milestones will form the foundation of the next year’s assessment. The results of the Annual Assessment will be sent to the Grantee by email within sixty days following completion of same.

Grant payment

Blood Cancer United pays research grants quarterly in March, June, September, and December. Payments are contingent upon reporting requirements; all report approvals must be up to date in order for payment to be processed. A list of sent payments can be viewed in the Blood Cancer United Research Portal (FLUXX) under Dispersed Payments.

Transfers

Blood Cancer United approval is required at least 30 days prior to an award's transfer to a new institution or laboratory. In order to submit a request for transfer, complete a Special Requests report in the Blood Cancer United Research Portal (FLUXX). This report includes a form, which must be signed by the awardee, sponsor and signatory of the pre-transfer institution, and sponsor, signatory, and financial officer of the post-transfer institution. Your request will be reviewed, and an Blood Cancer United research administrator will contact the awardee with confirmation or a request for further information. Approval is contingent upon continued research support and sponsorship, fitness of the new research environment, and eligibility of the post-transfer institution to receive Blood Cancer United funding (must be a not-for-profit research or academic institution).

Once the transfer request is approved, Blood Cancer United will provide an Assignment and Amendment Agreement to the pre-transfer institution. The pre-transfer institution must provide all required signatures and then pass along to the post-transfer institution to be returned to Blood Cancer United. 

Leaves of absence

Blood Cancer United approval is required at least 30 days prior to the interruption of an award. Leaves of absence may not exceed 1 year in duration. In order to submit a request for leave of absence, complete a Special Requests report in the Blood Cancer United Research Portal (FLUXX).If the request is approved, funding of the award will be suspended during the leave period, and the award term will be extended for a period equal to the duration of the suspension (e.g. following an approved 1-year leave of absence, an award originally scheduled to end 6/30/2022 will end 6/30/2023).

No-cost extensions

In the final year of funding, Grantees may request a one-year no-cost extension. At the end of the no-cost extension period, any funds remaining must be returned to Blood Cancer United. To request a no-cost extension, complete a Special Requests report in the Blood Cancer United Research Portal (FLUXX). If the request is approved, the Grant period will be extended for one year, and final reports will be due 60 days following the new end date. The final payment will be paid once final reports are received and approved by Blood Cancer United.